1-6 of 6
Avi Ashkenazi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity

Yiyuan Yin, Stevan Djakovic, Scot Marsters, Janet Tien, Jing Peng, Jarrod Tremayne, Genee Lee, Richard M. Neve, Yan Wu, Mark Merchant, Avi Ashkenazi, Paul J. Carter
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (10): 2270–2278.
https://doi.org/10.1158/1535-7163.MCT-14-1050
Published: 05 October 2015
View article titled, Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Open the PDF for Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

Kilian M. Gust, David J. McConkey, Shannon Awrey, Paul K. Hegarty, Jing Qing, Jolanta Bondaruk, Avi Ashkenazi, Bogdan Czerniak, Colin P. Dinney, Peter C. Black
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (7): 1245–1254.
https://doi.org/10.1158/1535-7163.MCT-12-1150
Published: 07 July 2013
View article titled, Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer
Open the PDF for Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer in another window
Journal Articles

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2541–2546.
https://doi.org/10.1158/1535-7163.MCT-12-0358
Published: 08 November 2012
View article titled, Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Open the PDF for Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist in another window
Journal Articles

Abstract C63: Targeting FGFR3 with monoclonal antibody impairs bladder cancer growth in vivo.

Xiangnan Du, Hao Li, Ellen Ingalla, Sarajane Ross, Dorothy French, Janet Tien, Avi Ashkenazi, Jing Qing
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C63.
https://doi.org/10.1158/1535-7163.TARG-11-C63
Published: 12 November 2011
View article titled, Abstract C63: Targeting FGFR3 with monoclonal antibody impairs bladder cancer growth in vivo.
Journal Articles

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

Yonglei Shang, Yifan Mao, Jennifer Batson, Suzie J. Scales, Gail Phillips, Mark R. Lackner, Klara Totpal, Simon Williams, Jihong Yang, Zhijun Tang, Zora Modrusan, Christine Tan, Wei-Ching Liang, Siao Ping Tsai, Alexander Vanderbilt, Kenji Kozuka, Klaus Hoeflich, Janet Tien, Sarajane Ross, Congfen Li, Sang Hoon Lee, An Song, Yan Wu, Jean-Philippe Stephan, Avi Ashkenazi, Jiping Zha
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2599–2608.
https://doi.org/10.1158/1535-7163.MCT-07-2401
Published: 11 September 2008
View article titled, Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Open the PDF for Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake in another window
Includes: Supplementary data
Journal Articles

Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma

Dylan Daniel, Becky Yang, Klara Totpal, Klaus Wagner, Sharon Yee, Sarajane Ross, Avi Ashkenazi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B32.
Published: 01 November 2007
View article titled, Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma